Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study-Reference-Cited by-同舟云学术

Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

Published:2023-07 Issue:7 Volume:23 Page:816-827
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Chemaitelly Hiam,Ayoub Houssein H,Tang Patrick,Coyle Peter,Yassine Hadi M,Al Thani Asmaa A,Al-Khatib Hebah A,Hasan Mohammad R,Al-Kanaani Zaina,Al-Kuwari Einas,Jeremijenko Andrew,Kaleeckal Anvar Hassan,Latif Ali Nizar,Shaik Riyazuddin Mohammad,Abdul-Rahim Hanan F,Nasrallah Gheyath K,Al-Kuwari Mohamed Ghaith,Butt Adeel A,Al-Romaihi Hamad Eid,Al-Thani Mohamed H,Al-Khal Abdullatif,Bertollini Roberto,Faust Jeremy Samuel,Abu-Raddad Laith J

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference32 articles.

1. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar;Chemaitelly;N Engl J Med,2021

2. Duration of immune protection of SARS-CoV-2 natural infection against reinfection;Chemaitelly;J Travel Med,2022

3. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study;Tartof;Lancet Respir Med,2023

4. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar;Abu-Raddad;N Engl J Med,2022

5. Duration of mRNA vaccine protection against SARS-CoV-2 omicron BA.1 and BA.2 subvariants in Qatar;Chemaitelly;Nat Commun,2022

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B);International Journal of Infectious Diseases;2024-09

2. Vaccination against COVID-19 in a post-pandemic era;COVID-19: An Update;2024-09-01

3. SARS-CoV-2 Omicron XBB.1 variant outbreak in a defined cohort: an epidemiological investigation incorporating longitudinal assessment of humoral response;International Journal of Infectious Diseases;2024-09

4. Effect of metabolic dysfunction‐associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant;Journal of Gastroenterology and Hepatology;2024-08-17

5. All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data;F1000Research;2024-08-05